Review: Evaluating combination therapies for asthma: Pros, cons, and comparative benefits

Therapeutic Advances in Respiratory Disease

Volumn 2, Issue 3, 2008, Pages 149-161

  Bjermer, Leif ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

asthma; combination therapy; inhaled corticosteroid; leukotriene receptor antagonist; long acting 2 agonist

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; BUDESONIDE PLUS TERBUTALINE; CORTICOSTEROID; FLUTICASONE PLUS MONTELUKAST; FLUTICASONE PLUS SALMETEROL; FORMOTEROL; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; PLACEBO; PREDNISOLONE; PREDNISONE; SALBUTAMOL; SALMETEROL; TERBUTALINE;

ADD ON THERAPY; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHODILATING ACTIVITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; EXERCISE INDUCED ASTHMA; HUMAN; LOW DRUG DOSE; LUNG FUNCTION; MAINTENANCE THERAPY; MONOTHERAPY; PATIENT COMPLIANCE; PHENOTYPE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SEVERE PERSISTENT ASTHMA; TREATMENT RESPONSE;

ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ASTHMA; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; HUMANS; LEUKOTRIENE ANTAGONISTS; NEBULIZERS AND VAPORIZERS; PHENOTYPE;

EID: 68749098714     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465808092280     Document Type: Review

References (64)

1. Baiardini, I., Braido, F., Giardini, A., Majani, G., Cacciola, C., Rogaku, A. et al. (2006) Adherence to treatment: assessment of an unmet need in asthma. J Investig Allergol Clin Immunol 16: 218-223.
2. Bijl-Hofland, I.D., Cloosterman, S.G., Folgering, H.T., Akkermans, R.P. and van Schayck, C.P. (1999) Relation of the perception of airway obstruction to the severity of asthma. Thorax 54: 15-19.
3. Bjermer, L., Bisgaard, H., Bousquet, J., Fabbri, L.M., Greening, A.P., Haahtela, T. et al. (2003) Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ 327: 1-6.
4. Bousquet, J., Ben-Joseph, R., Messonnier, M., Alemao, E. and Gould, A.L. (2002) A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma. Clin Ther 24: 1-20.
5. Bousquet, J., Gaugris, S., Kocevar, V.S., Zhang, Q., Yin, D.D., Polos, P.G. et al. (2005) Increased risk of asthma attacks and emergency visits among asthma patients with allergic rhinitis: a subgroup analysis of the investigation of montelukast as a partner agent for complementary therapy [corrected]. Clin Exp Allergy 35: 723-727.
6. Bousquet, J., Van, C.P. and Khaltaev, N. (2001) Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108: S147-S334.
7. Busse, W.W., Casale, T.B., Dykewicz, M.S., Meltzer, E.O., Bird, S.R., Hustad, C.M. et al. (2006) Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity. Ann Allergy Asthma Immunol 96: 60-68.
8. Chalmers, G.W., Macleod, K.J., Little, S.A., Thomson, L.J., McSharry, C.P. and Thomson, N.C. (2002) Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 57: 226-230.
9. Chetta, A., Gerra, G., Foresi, A., Zaimovic, A., Del, D.M., Chittolini, B. et al. (1998) Personality profiles and breathlessness perception in outpatients with different gradings of asthma. Am J Respir Crit Care Med 157: 116-122.
10. Corren, J. (1997) Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol 99: S781-S786.
11. Currie, G.P., Lee, D.K., Haggart, K., Bates, C.E. and Lipworth, B.J. (2003) Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med 167: 1232-1238.
12. Currie, G.P. and Lipworth, B.J. (2002) Bronchoprotective effects of leukotriene receptor antagonists in asthma: a meta-analysis. Chest 122: 146-150.
13. D'Urzo, A.D. (2005) CONtrol Centered Patient Treatment (CONCEPT). Clin Ther 27: 1312-1315.
14. Ducharme, F.M., Lasserson, T.J. and Cates, C.J. (2006) Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev: CD003137.
15. Edelman, J.M., Turpin, J.A., Bronsky, E.A., Grossman, J., Kemp, J.P., Ghannam, A.F. et al. (2000) Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann Intern Med 132: 97-104.
16. Fauler, J. and Frolich, J.C. (1997) Cigarette smoking stimulates cysteinyl leukotriene production in man. Eur J Clin Invest 27: 43-47.
17. Fish, J.E., Israel, E., Murray, J.J., Emmett, A., Boone, R., Yancey, S.W. et al. (2001) Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy. Chest 120: 423-430.
18. FitzGerald, J.M., Boulet, L.P. and Follows, R.M. (2005) The CONCEPT trial: a 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther 27: 393-406.
19. FitzGerald, J.M., Sears, M.R., Boulet, L.P., Becker, A.B., McIvor, A.R., Ernst, P. et al. (2003) Adjustable maintenance dosing with budesonide/ formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study. Can Respir J 10: 427-434.
20. GINA - The Global Strategy for Asthma Management and Prevention 2006. Available at http://www.ginasthma.com/GuidelinesResources.asp. Accessed 12 March 2008.
21. Greening, A.P., Ind, P.W., Northfield, M. and Shaw, G. (1994) Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 344: 219-224.
22. Herland, K., Akselsen, J.P., Skjonsberg, O.H. and Bjermer, L. (2005) How representative are clinical study patients with asthma or COPD for a larger “real life” population of patients with obstructive lung disease? Respir Med 99: 11-19.
23. Horne, R., Price, D., Cleland, J., Costa, R., Covey, D., Gruffydd-Jones, K. et al. (2007) Can asthma control be improved by understanding the patient's perspective? BMC Pulm Med 7: 8.
24. Jonasson, G., Carlsen, K.H. and Mowinckel, P. (2000) Asthma drug adherence in a long term clinical trial. Arch Dis Child 83: 330-333.
25. Kerstjens, H.A., Overbeek, S.E., Schouten, J.P., Brand, P.L. and Postma, D.S. (1993) Airways hyperresponsiveness, bronchodilator response, allergy and smoking predict improvement in FEV1 during long-term inhaled corticosteroid treatment. Dutch CNSLD Study Group. Eur Respir J 6: 868-876.
26. Kuna, P., Peters, M.J., Manjra, A.I., Jorup, C., Naya, I.P., Martinez-Jimenez, N.E. et al. (2007) Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 61: 725-736.
27. Laforest, L., Van, G.E., Devouassoux, G., Osman, L.M., Brice, K., Massol, J. et al. (2007) Asthmatic patients’ poor awareness of inadequate disease control: a pharmacy-based survey. Ann Allergy Asthma Immunol 98: 146-152.
28. Laviolette, M., Malmstrom, K., Lu, S., Chervinsky, P., Pujet, J.C., Peszek, I. et al. (1999) Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med 160: 1862-1868.
29. Lazarus, S.C., Boushey, H.A., Fahy, J.V., Chinchilli, V.M., Lemanske Jr, R.F., Sorkness, C.A. et al. (2001) Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 285: 2583-2593.
30. Lazarus, S.C., Chinchilli, V.M., Rollings, N.J., Boushey, H.A., Cherniack, R., Craig, T.J. et al. (2007) Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 175: 783-790.
31. Leff, J.A., Busse, W.W., Pearlman, D., Bronsky, E.A., Kemp, J., Hendeles, L. et al. (1998) Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 339: 147-152.
32. Lipworth, B.J. (2001) Fluticasone propionate/ salmeterol combination. J Allergy Clin Immunol 107: 746.
33. Lipworth, B.J. and Jackson, C.M. (2002) Bronchodilator reversibility to albuterol predicts bronchodilator response to salmeterol. Chest 121: 1382.
34. McGavin, J.K., Goa, K.L. and Jarvis, B. (2001) Inhaled budesonide/formoterol combination. Drugs 61: 71-78.
35. McIvor, R.A., Pizzichini, E., Turner, M.O., Hussack, P., Hargreave, F.E. and Sears, M.R. (1998) Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med 158: 924-930.
36. Nelson, H.S., Busse, W.W., Kerwin, E., Church, N., Emmett, A., Rickard, K. et al. (2000) Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast. J Allergy Clin Immunol 106: 1088-1095.
37. Nelson, H.S., Weiss, S.T., Bleecker, E.R., Yancey, S.W., Dorinsky, P.M.; SMART Study Group. (2006) The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129: 15-26.
38. Nih/Nhlbi (2007) Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 120: S94-138.
39. O'Brien, K. and Bukstein, D. (2001) What is “more effective asthma control”? J Allergy Clin Immunol 107: 1107-1109.
40. O'Byrne, P.M., Bisgaard, H., Godard, P.P., Pistolesi, M., Palmqvist, M., Zhu,Y. et al. (2005) Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171: 129-136.
41. Pauwels, R.A., Lofdahl, C.G., Postma, D.S., Tattersfield, A.E., O'Byrne, P., Barnes, P.J. et al. (1997) Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337: 1405-1411.
42. Pedersen, B., Dahl, R., Karlstrom, R., Peterson, C.G. and Venge, P. (1996) Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking. Am J Respir Crit Care Med 153: 1519-1529.
43. Philip, G., Nayak, A.S., Berger, W.E., Leynadier, F., Vrijens, F., Dass, S.B. et al. (2004) The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis. Curr Med Res Opin 20: 1549-1558.
44. Pizzichini, E., Leff, J.A., Reiss, T.F., Hendeles, L., Boulet, L.P., Wei, L.X. et al. (1999) Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 14: 12-18.
45. Price, D.B., Hernandez, D., Magyar, P., Fiterman, J., Beeh, K.M., James, I.G. et al. (2003) Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 58: 211-216.
46. Rabe, K.F., Atienza, T., Magyar, P., Larsson, P., Jorup, C. and Lalloo, U.G. (2006a) Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 368: 744-753.
47. Rabe, K.F., Pizzichini, E., Stallberg, B., Romero, S., Balanzat, A.M., Atienza, T. et al. (2006b) Budesonide/ formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 129: 246-256.
48. Ramage, L., Lipworth, B.J., Ingram, C.G., Cree, I.A. and Dhillon, D.P. (1994) Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 88: 363-368.
49. Rau, J.L. (2005) Determinants of patient adherence to an aerosol regimen. Respir Care 50: 1346-1356.
50. Reiss, T.F., Chervinsky, P., Dockhorn, R.J., Shingo, S., Seidenberg, B. and Edwards, T.B. (1998) Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic
51. asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch Intern Med 158: 1213-1220.
52. Scicchitano, R., Aalbers, R., Ukena, D., Manjra, A., Fouquert, L., Centanni, S. et al. (2004) Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 20: 1403-1418.
53. Simons, F.E., Villa, J.R., Lee, B.W., Teper, A.M., Lyttle, B., Aristizabal, G. et al. (2001) Montelukast added to budesonide in children with persistent asthma: a randomized, double-blind, crossover study. J Pediatr 138: 694-698.
54. Stallberg, B., Olsson, P., Jorgensen, L.A., Lindarck, N. and Ekstrom, T. (2003) Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing. Int J Clin Pract 57: 656-661.
55. Storms, W., Chervinsky, P., Ghannam, A.F., Bird, S., Hustad, C.M. and Edelman, J.M. (2004) A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir Med 98: 1051-1062.
56. Tattersfield, A.E., Postma, D.S., Barnes, P.J., Svensson, K., Bauer, C.A., O'Byrne, P.M. et al. (1999) Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 160: 594-599.
57. Thomas, M., Leather, D. and Price, D. (2006) High-dose inhaled corticosteroids and add-on therapy use in adults with asthma in the UK in 2003: an observational study. Prim Care Respir J 15: 166-172.
58. Thomson, N.C., Chaudhuri, R. and Livingston, E. (2004) Asthma and cigarette smoking. Eur Respir J 24: 822-833.
59. Vaquerizo, M.J., Casan, P., Castillo, J., Perpina, M., Sanchis, J., Sobradillo, V. et al. (2003) Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax 58: 204-210.
60. Villaran, C., O'Neill, S.J., Helbling, A., van Noord, J.A., Lee, T.H., Chuchalin, A.G. et al. (1999) Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. J Allergy Clin Immunol 104: 547-553.
61. Virchow, J.C. and Bachert, C. (2006) Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med 100: 1952-1959.
62. Vogelmeier, C., D'Urzo, A., Pauwels, R., Merino, J.M., Jaspal, M., Boutet, S. et al. (2005) Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 26: 819-828.
63. Williams, L.K., Pladevall, M., Xi, H., Peterson, E.L., Joseph, C., Lafata, J.E. et al. (2004) Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 114: 1288-1293.
64. Yates, D.H., Kharitonov, S.A. and Barnes, P.J. (1996) An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist. Am J Respir Crit Care Med 154: 1603-1607.